Disclosures for "Safety and Tolerability of P2B001 in Patients with Early Parkinson’s Disease: Analysis of an Integrated Phase 2 and 3 Safety Database"
-
The institution of Dr. DeMarcaida has received research support from Pharma2B. The institution of Dr. DeMarcaida has received research support from Neuroderm. The institution of Dr. DeMarcaida has received research support from Sage Therapeutics.
-
Dr. Litman has received personal compensation for serving as an employee of PHARMA 2B.
-
Mrs. Friedman has received personal compensation for serving as an employee of Pharma Two B.
-
Dr. Fitzer-Attas has received personal compensation for serving as an employee of Mitsubishi Tanabe Pharma America. The institution of Dr. Fitzer-Attas has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Cyclerion. The institution of Dr. Fitzer-Attas has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Pharma Two B. The institution of Dr. Fitzer-Attas has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Golden Heart Flower. The institution of Dr. Fitzer-Attas has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for B-Portal Biologics. Dr. Fitzer-Attas has stock in Golden Heart Flower.